Literature DB >> 16829048

Early stage vision in schizophrenia and schizotypal personality disorder.

Brian F O'Donnell1, Andrew Bismark, William P Hetrick, Misty Bodkins, Jenifer L Vohs, Anantha Shekhar.   

Abstract

Previous studies of visual perception have reported deficits in contrast sensitivity and dot motion discrimination in schizophrenia. We tested whether these deficits also appear in schizotypal personality disorder (SPD). SPD appears to be genetically and symptomatically related to schizophrenia, but without the marked psychosocial impairment associated with psychotic disorders. The present study investigated contrast sensitivity for moving and static gratings, form discrimination and dot motion discrimination in 24 patients with schizophrenia or schizoaffective disorder (SZ), 16 individuals with SPD, and 40 control subjects. SZ, but not SPD subjects, showed impairments on tests of contrast sensitivity for static and moving gratings, form discrimination in noise, and dot motion discrimination. Visual performance did not differ between medicated SZ patients and patients withdrawn from medication. These results confirm early stage visual deficits in schizophrenia regardless of medication status. SPD subjects, in contrast, show intact early stage visual processing despite the presence of marked schizotypal symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829048     DOI: 10.1016/j.schres.2006.05.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  A review of visual aftereffects in schizophrenia.

Authors:  Katharine N Thakkar; Steven M Silverstein; Jan W Brascamp
Journal:  Neurosci Biobehav Rev       Date:  2019-03-30       Impact factor: 8.989

2.  Deficient visual sensitivity in schizotypal personality disorder.

Authors:  Brendon W Kent; Zachary A Weinstein; Vincent Passarelli; Yue Chen; Larry J Siever
Journal:  Schizophr Res       Date:  2010-06-11       Impact factor: 4.939

3.  Disturbances of visual motion perception in bipolar disorder.

Authors:  Rebecca A O'Bryan; Colleen A Brenner; William P Hetrick; Brian F O'Donnell
Journal:  Bipolar Disord       Date:  2014-01-02       Impact factor: 6.744

4.  Psychometrically matched tasks evaluating differential fMRI activation during form and motion processing.

Authors:  Andrea N Snyder; Marcie A Bockbrader; Angela M Hoffa; Mario A Dzemidzic; Thomas M Talavage; Donald Wong; Mark J Lowe; Brian F O'Donnell; Anantha Shekhar
Journal:  Neuropsychology       Date:  2011-09       Impact factor: 3.295

5.  Visual perception in prediagnostic and early stage Huntington's disease.

Authors:  Brian F O'Donnell; Tanya M Blekher; Marjorie Weaver; Kerry M White; Jeanine Marshall; Xabier Beristain; Julie C Stout; Jacqueline Gray; Joanne M Wojcieszek; Tatiana M Foroud
Journal:  J Int Neuropsychol Soc       Date:  2008-05       Impact factor: 2.892

6.  Compromised speed discrimination among schizophrenia patients when viewing smooth pursuit targets.

Authors:  Brett A Clementz; Jennifer E McDowell; Karen R Dobkins
Journal:  Schizophr Res       Date:  2007-07-12       Impact factor: 4.939

7.  Diminished parietal cortex activity associated with poor motion direction discrimination performance in schizophrenia.

Authors:  Jun Wang; Ryan Brown; Karen R Dobkins; Jennifer E McDowell; Brett A Clementz
Journal:  Cereb Cortex       Date:  2009-11-13       Impact factor: 5.357

8.  Temporal processing dysfunction in schizophrenia.

Authors:  Christine A Carroll; Jennifer Boggs; Brian F O'Donnell; Anantha Shekhar; William P Hetrick
Journal:  Brain Cogn       Date:  2008-02-11       Impact factor: 2.310

9.  New visual information processing abnormality biomarker for the diagnosis of Schizophrenia.

Authors:  Ivan Koychev; Wael El-Deredy; John Francis William Deakin
Journal:  Expert Opin Med Diagn       Date:  2011-07-01

10.  Stronger tilt aftereffects in persons with schizophrenia.

Authors:  Katharine N Thakkar; Livon Ghermezi; Steven M Silverstein; Rachael Slate; Beier Yao; Eric D Achtyes; Jan W Brascamp
Journal:  J Abnorm Psychol       Date:  2020-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.